# TP63

Source: https://onco.cc/targets/tp63/  
OnCo record `tp63` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TP63 (Tumour protein 63) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Skin cancer, Non-Hodgkin lymphoma and 5 more.

## Summary

Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. Isoform 2 activates RIPK4 transcription.

Open Targets scores its association with cancer at 0.80 (direct and indirect evidence; datatypes affected pathway 0.40, literature 0.98, genetic association 0.72, somatic mutation 0.83, animal model 0.75). IntOGen calls it a driver in 5 cohorts (1 activating, 4 loss-of-function), covering Bladder Urothelial Carcinoma, Cervical Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Neuroblastoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: tumor protein p63; Tumor protein 63; p51; SHFM4; EEC3; p63; p73L; OFC8; p73H; p53CP; p40; TP73L; TP53L; TP53CP
- Tags: cancer-genes-wave
- Symbol: TP63
- Class: transcription
- Biology: Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. Isoform 2 activates RIPK4 transcription. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. Involved in Notch signalling by probably inducing JAG1 and JAG2. Plays a role in the regulation of epithelial morphogenesis. Location: Nucleus (UniProt). Locus 3q28 (HGNC).
- Where found: Lung cancer: Open Targets association 0.69 with lung cancer (MONDO_0008903); Skin cancer: Open Targets association 0.68 with skin cancer (MONDO_0002898); Non-Hodgkin lymphoma: Open Targets association 0.64 with non-Hodgkin lymphoma (MONDO_0018908); Leukaemia: Open Targets association 0.60 with leukaemia (MONDO_0005059); Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA); Cervical cancer: IntOGen driver in 1 cohort (CESC)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 4 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:15979: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15979
- UniProt Q9H3D4: https://www.uniprot.org/uniprotkb/Q9H3D4/entry
- NCBI Gene 8626: https://www.ncbi.nlm.nih.gov/gene/8626
- Ensembl ENSG00000073282: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000073282

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Cervical cancer](https://onco.cc/cancers/cervical/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)

---
JSON: https://onco.cc/api/v1/entities/tp63.json